Mark Puricelli, DO
Neurology · Des Moines, IANPI 1760596514
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $38,905 of the $45,168 with a category attached, or 86.1%. 31 manufacturers reported payments, led by AbbVie at 47.9% of the total. Reporting peaked in 2019 at $20,344 and has fallen 96.8% since, to $651 in 2025. Among neurology clinicians in IA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 311 payments — averaging $145.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$22K
- Amgen$21K
- Lundbeck LLC$604
- Teva Pharmaceuticals USA, Inc.$235
- Biogen$222
- TG Therapeutics, Inc.$200
- plus $1K from 25 others
What the payments were for
- Speaking & faculty fees$38,90586%
- Travel & lodging$8802%
- Food & beverage$5,38312%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 146 | $21,652 |
| Amgen | 30 | $20,820 |
| Lundbeck LLC | 9 | $604 |
| Teva Pharmaceuticals USA, Inc. | 24 | $235 |
| Biogen | 9 | $222 |
| TG Therapeutics, Inc. | 6 | $200 |
| Novartis | 16 | $190 |
| Sanofi | 4 | $168 |
| Supernus Pharmaceuticals, Inc. | 20 | $156 |
| Pfizer | 9 | $156 |
| Vanda Pharmaceuticals Inc. | 1 | $105 |
| UCB, Inc. | 5 | $98 |
| EMD Serono, Inc. | 3 | $79 |
| Lilly USA, LLC | 5 | $61 |
| Eisai Inc. | 3 | $60 |
| Acorda Therapeutics, Inc | 3 | $49 |
| Sunovion Pharmaceuticals Inc. | 3 | $37 |
| CSL Behring | 1 | $32 |
| Adamas Pharmaceuticals, Inc. | 2 | $29 |
| GE HealthCare | 1 | $29 |
| Genentech USA, Inc. | 1 | $22 |
| Argenx US, Inc. | 1 | $21 |
| AstraZeneca | 1 | $21 |
| Vertical Pharmaceuticals, LLC | 1 | $18 |
| Tanabe Pharma America, Inc. | 1 | $17 |
| Kyowa Kirin, Inc. | 1 | $16 |
| Medtronic | 1 | $16 |
| Jazz Pharmaceuticals Inc. | 1 | $15 |
| Bristol Myers Squibb | 1 | $14 |
| Alnylam Pharmaceuticals Inc. | 1 | $14 |
| Promius Pharma LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$45,168 in reported general payments places this provider in the 90th percentile of 132 neurology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UbrelvyUbrogepant | 99 | $155,853 |
| Nurtec OdtRimegepant Sulfate | 82 | $99,304 |
| QuliptaAtogepant | 74 | $92,971 |
| Emgality PenGalcanezumab-Gnlm | 79 | $77,267 |
| Aimovig AutoinjectorErenumab-Aooe | 70 | $52,869 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 51 | $43,454 |
| Ajovy SyringeFremanezumab-Vfrm | 19 | $13,810 |
| LamictalLamotrigine | 26 | $9,057 |
| ReyvowLasmiditan Succinate | 12 | $8,760 |
| Pramipexole ErPramipexole Di-Hcl | 22 | $8,186 |
| Levetiracetam | 229 | $7,488 |
| Gabapentin | 320 | $6,788 |
| Sumatriptan Succinate | 173 | $6,760 |
| Carbamazepine ErCarbamazepine | 26 | $5,492 |
| Lacosamide | 21 | $3,619 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Qulipta | $21,652 | $248,824173 claims |
| PfizerNurtec Odt | $156 | $99,30482 claims |
| Lilly USA, LLCReyvow | $61 | $8,76012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 132 neurology providers in Iowa.
Other neurology in Des Moines
- Bruce HughesDes Moines$1.8M
- Michael JacobyDes Moines$243K
- Lynn RankinDes Moines$181K
- Wendy ZadehDes Moines$134K
- Paul BabikianDes Moines$107K
- Keith KohoutDes Moines$36K
- Erik ArnesonDes Moines$10K
- John WrightDes Moines$9K
- Lynn StruckDes Moines$6K
- Irving WolfeDes Moines$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.